ANAB
USDAnaptysBio Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$35.970
Máximo
$36.500
Mínimo
$34.595
Volume
0.76M
Fundamentos da empresa
Capitalização de mercado
971.8M
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
0.52M
Bolsa de valores
NMS
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec.
Anaptys Announces Participation in November Investor Conferences
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president
Stifel Maintains Buy on AnaptysBio, Raises Price Target to $80
Stifel analyst Alex Thompson maintains AnaptysBio with a Buy and raises the price target from $55 to $80.
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
New data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including
Ações relacionadas
CC
Chemours Company (The)
SGRY
Surgery Partners Inc.
GAM
General American Investors Inc.
SEZL
Sezzle Inc.
AGNCO
AGNC Investment Corp. Depositary Shares each representing a 1/1000th interest in a share of 6.50% Series E Fixed-to-Floating Cumulative Redeemable Preferred Stock
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.